Y
Yon-Dschun Ko
Researcher at National Institutes of Health
Publications - 91
Citations - 7455
Yon-Dschun Ko is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 32, co-authored 90 publications receiving 6240 citations. Previous affiliations of Yon-Dschun Ko include University of Cologne & Ruhr University Bochum.
Papers
More filters
Journal ArticleDOI
A phase III trial of topotecan and whole brain radiation (WBRT) therapy for patients with CNS metastases due to lung cancer
Yon-Dschun Ko,T. Neuhaus,R P Muller,Gerhard G. Grabenbauer,J P Hedde,Heinrich Schüller,M. Kocher,S. Stier,R. Ullrich,Rainer Fietkau +9 more
TL;DR: An open, randomized, prospective, multicentric phase III trial comparing WBRT with topotecan in patients with CNS-metastases due to SCLC or NSCLC, with promising data raised in a phase I/II trial.
Journal Article
Risk of estrogen receptor positive- and negative-breast cancer and SNP rs13387042 on 2q35
Roger L. Milne,Javier Benítez,H Nevanlinna,Tuomas Heikkinen,Kristiina Aittomäki,Carl Blomqvist,José Ignacio Arias,Maria Pilar Zamora,Barbara Burwinkel,Claus R. Bartram,A. Meindl,Rita K. Schmutzler,Cox A,Ian W. Brock,Graeme Elliott,MW Reed,MC Southey,Letitia D. Smith,Amanda B. Spurdle,John L. Hopper,Fergus J. Couch,Janet E. Olson,Xianshu Wang,Zachary S. Fredericksen,Peter Schürmann,Michael Bremer,Peter Hillemanns,Thilo Dörk,Peter Devilee,van, Asperen, Cj,R.A.E.M. Tollenaar,Caroline Seynaeve,Per Hall,Kamila Czene,Jianjun Liu,Yuqing Li,S. Ahmed,Alison M. Dunning,Melanie Maranian,Paul D.P. Pharoah,Georgia Chenevix-Trench,Jonathan Beesley,kConFab Investigators,Natalia Bogdanova,Antonenkova Nn,Zalutsky,Hoda Anton-Culver,Argyrios Ziogas,Hiltrud Brauch,Christina Justenhoven,Yon-Dschun Ko,Susanne Haas,P. A. Fasching,Reiner Strick,Arif B. Ekici,Matthias W. Beckmann,Graham G. Giles,Gianluca Severi,Laura Baglietto,Olivia Fletcher,Nichola Johnson,Isabel dos Santos Silva,Julian Peto,Clare Turnbull,Sarah Hines,Anthony Renwick,Nazneen Rahman,Børge G. Nordestgaard,Stig E. Bojesen,Henrik Flyger,Daehee Kang,Keun-Young Yoo,Dong-Young Noh,Arto Mannermaa,Kataja,Veli-Matti Kosma,M Garcia-Closas,S. Chanock,Jolanta Lissowska,Louise A. Brinton,Jenny Chang-Claude,Shan Wang-Gohrke,Chen-Yang Shen,Hui-Chun Wang,Jyh-Cherng Yu,Sou-Tong Chen,Marina Bermisheva,T Nikolaeva,Elza Khusnutdinova,Manjeet K. Humphreys,Jonathan J. Morrison,Radka Platte,Doug Easton +92 more
Journal ArticleDOI
Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.
Masyar Gardizi,Matthias Scheffler,Lukas C. Heukamp,Marc Bos,Kerstin Albus,Birgit Hayn,Yon-Dschun Ko,Andreas Schlesinger,Michael Brockmann,Monika Serke,Ulrich Gerigk,Khosro Hekmat,Erich Stoelben,Marcel Reiser,Roland Schnell,Stephan Schmitz,Konrad Frank,Reinhard Buettner,Jürgen Wolf,Thomas Zander +19 more
TL;DR: In this article, the frequency and characteristics of patients with PIK3CA mutated lung tumors were reported and compared to other lung cancer types, including melanoma, lung cancer, and lung cancer.
Journal ArticleDOI
KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).
Rieke Frank,Matthias Scheffler,Sebastian Michels,Anna Eisert,Rieke Fischer,Katharina Koenig,Sabine Merkelbach-Bruse,Monika Serke,Yon-Dschun Ko,Ulrich Gerigk,Thomas Geist,Lukas C. Heukamp,Reinhard Büttner,Juergen Wolf +13 more
TL;DR: This data indicates that down-regulation in the KEAP1-NFE2L2 pathway is associated with an increased tumor growth, resistence towards cytostatic drugs and reduced survival rates in patients with NSCLC.
Journal ArticleDOI
Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial
Lisa B. Leypoldt,Anne Marie Asemissen,Britta Besemer,Mathias Haenel,Igor Wolfgang Blau,Martin Görner,Yon-Dschun Ko,Hans Christian Reinhardt,Peter Staib,Christoph Mann,Raphael Lutz,Markus Munder,Ullrich Graeven,Rudolf Peceny,Hans Salwender,Anna Jauch,Manola Zago,Axel Benner,Diana Tichy,Carsten Bokemeyer,Hartmut Goldschmidt,Katja Weisel +21 more
TL;DR: A prespecified interim analysis following induction therapy with the quadruplet regimen isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed HR MM patients, finding Isa-KRd induction induces rapid and deep responses and the overall safety profile is consistent with previous reports.